Skip to main content

West Pharmaceutical Services, I (WST) Stock Analysis

Recovery setup

Buy WaitModerate Confidence

Healthcare · Medical Instruments & Supplies

Wait for pullback to $258.42. At $298.42 the A.R:R is 0.1:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $258.42 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Geographic: sales outside the U.S. (56.7%); Analyst target reached - limited upside remaining.

West Pharmaceutical Services designs and manufactures containment and delivery systems for injectable drugs via two segments: Proprietary Products (packaging, delivery devices) and Contract-Manufactured Products. Top 10 customers account for 47.6% of 2025 net sales; one customer... Read more

$298.42+17.6% A.UpsideScore 6.2/10#1 of 25 Medical Instruments & Supplies
Entry $258.42(Ma200 Sticky)Stop $237.05Target $304.37(analyst − 13%)A.R:R 0.1:1Setup A.R:R 3.0:1
Analyst target$349.85+17.2%13 analysts
$304.37our TP
$298.42price
$349.85mean
$400

Wait for pullback to $258.42. At $298.42 the A.R:R is 0.1:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $258.42 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Geographic: sales outside the U.S. (56.7%); Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 73. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 6.2/10, moderate confidence.

Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 83d clear, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

Val3.7Qual6.9Grw8.8Mom6.7Sent7.5Ins5.0Peer4.8Tech5.0Risk5.46.2OVERALL

Thesis

Rewards
Strong earnings beat streak (4/4)
Positive news sentiment (+0.67)
Strong growth profile
Risks
Concentration risk — Geographic: sales outside the U.S. (56.7%)
Analyst target reached - limited upside remaining
Expensive valuation

Key Metrics

P/E (TTM)39.8
P/E (Fwd)31.2
Mkt Cap$21.0B
EV/EBITDA23.9
Profit Mgn16.8%
ROE19.1%
Rev Growth21.0%
Beta1.15
Dividend0.30%
Rating analysts23

Quality Signals

Piotroski F9/9

Options Flow

P/C2.22bearish
IV48%normal
Max Pain$220-26.3% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHGeographicsales outside the U.S.57%
    10-K Item 1: 'Sales outside of the U.S. accounted for 56.7% of our consolidated net sales in 2025'
  • MEDIUMCustomertop-10 customers48%
    10-K Item 1: 'Our ten largest customers accounted for 47.6% of our consolidated net sales in 2025'
  • MEDIUMCustomerone customer (15.8% of net sales)16%
    10-K Item 1: 'one of these customers individually accounted for more than 10% of consolidated net sales, at 15.8% or $485.9 million'
  • MEDIUMSuppliersingle-source suppliers for critical raw materials
    10-K Item 1: 'we rely on single-source suppliers for certain critical raw materials'

Material Events(8-K, last 90d)

  • 2026-03-09Item 5.02MEDIUM
    President, CEO and Board Chair Eric M. Green announced intent to retire once successor is hired (expected 2H 2026). Board engaged executive recruiting firm; no successor named. Green to remain in role until transition occurs.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ev Ebitda
0.0
Pe
3.0
Forward Pe
3.8
Peg Ratio
3.8
Analyst Target
5.0
Ps
5.8
Forward P/E: 31.2xPEG: 2.84
GatesA.R:R 0.1 < 1.5@spotMomentum 6.7>=5.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.60EARNINGS PROXIMITY 83d clearSEMI CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
73 · Overbought
↑ 20D MA↑ 50D MA↑ 200D MADEATH CROSSSupport $251.27Resistance $320.09

Price Targets

$237
$258
$304
A.Upside+2.0%
A.R:R0.1:1
Setup A.R:R (at entry)3.0:1

Position Sizing

ConvictionMedium conviction
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Target reached (2.0% upside)
! NEWS_MOD=+2: HOLD_IF_HOLDING → STRONG_BUY_WAIT
! Reward/Risk 0.1:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-23 (83d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is WST stock a buy right now?

Wait for pullback to $258.42. At $298.42 the A.R:R is 0.1:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $258.42 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Geographic: sales outside the U.S. (56.7%); Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 73. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $304.37 (+2.0%), stop $237.05 (−25.9%), Setup A.R:R 3.0:1. Score 6.2/10, moderate confidence.

What is the WST stock price target?

Take-profit target: $304.37 (+17.6% upside). Target $304.37 (+2.0%), stop $237.05 (−25.9%), Setup A.R:R 3.0:1. Stop-loss: $237.05.

What are the risks of investing in WST?

Concentration risk — Geographic: sales outside the U.S. (56.7%); Analyst target reached - limited upside remaining; Expensive valuation.

Is WST overvalued or undervalued?

West Pharmaceutical Services, I trades at a P/E of 39.8 (forward 31.2). TrendMatrix value score: 3.7/10. Verdict: Buy (Wait for Entry).

What do analysts say about WST?

23 analysts cover WST with a consensus score of 4.0/5. Average price target: $350.

What does West Pharmaceutical Services, I do?West Pharmaceutical Services designs and manufactures containment and delivery systems for injectable drugs via two...

West Pharmaceutical Services designs and manufactures containment and delivery systems for injectable drugs via two segments: Proprietary Products (packaging, delivery devices) and Contract-Manufactured Products. Top 10 customers account for 47.6% of 2025 net sales; one customer at 15.8% ($485.9M). International sales are 56.7% of net sales.

Related stocks: RMD (ResMed Inc.) · MMSI (Merit Medical Systems, Inc.) · ISRG (Intuitive Surgical, Inc.) · SOLV (Solventum Corporation) · STVN (Stevanato Group S.p.A.)